Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Meis homeobox 2 (MEIS2) mRNA 3'-untranslated region (3'-UTR) is a key regulatory segment of the MEIS2 transcript, which encodes a TALE-family homeodomain transcription factor essential for vertebrate development. This region contains evolutionary conserved sequences that serve as binding sites for microRNAs, most notably the miR-204/211 family, which post-transcriptionally repress MEIS2 expression to coordinate processes such as neurogenesis, cardiogenesis, and ocular development (PMID: 24507771). Mutations or deletions affecting the MEIS2 locus, or disruptions in its regulatory landscape, are primary causes of a syndromic form of intellectual disability characterized by cleft palate and cardiac defects (PMID: 25188571). In oncology, MEIS2 is often overexpressed and acts as a co-factor in leukemogenesis and neuroblastoma progression, making its regulatory elements attractive targets for intervention. Therapeutic strategies targeting the MEIS2 3'-UTR involve the use of antisense oligonucleotides (ASOs) to either induce mRNA degradation or block inhibitory microRNA binding to upregulate protein production. While promising for treating haploinsufficiency or overexpression, targeting this region requires high specificity to avoid disrupting the complex transcriptional networks MEIS2 participates in during development. Current research focuses on using these RNA-based tools to modulate MEIS2 levels in a tissue-specific manner to mitigate developmental or oncogenic pathologies.
Modulation of mRNA stability or translation efficiency through steric hindrance or recruitment of RNase H/RNA-induced silencing complex (RISC).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Meis homeobox 2 (MEIS2) mRNA 3'-untranslated region (MEIS2 3'-UTR).